Edwin Swiatlo, MD
Infectious Disease · New Orleans, LANPI 1982630075
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $16,680 of the $21,853 with a category attached, or 76.3%. Gilead accounts for 96.4% of it on its own, with 4 other manufacturers making up the rest. Reporting peaked in 2024 at $14,448 and has fallen 54.8% since, to $6,532 in 2025. Among infectious disease clinicians in LA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 90 payments — averaging $242.81 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Gilead$21K
- Viiv Healthcare Company$678
- Merck$56
- Theratechnologies Inc.$30
- Pfizer$16
Across 18 payments — averaging $2344.28 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Gilead$42K
What the payments were for
- Speaking & faculty fees$16,68076%
- Travel & lodging$2,66312%
- Food & beverage$2,51011%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Gilead | 71 | $21,074 |
| Viiv Healthcare Company | 14 | $678 |
| Merck | 3 | $56 |
| Theratechnologies Inc. | 1 | $30 |
| Pfizer | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$21,853 in reported general payments places this provider in the 90th percentile of 105 infectious disease providers in Louisiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| BiktarvyBictegrav/Emtricit/Tenofov Ala | 247 | $949,495 |
| SymtuzaDarunavir/Cob/Emtri/Tenof Alaf | 36 | $197,624 |
| CabenuvaCabotegravir/Rilpivirine | 29 | $182,910 |
| PrezcobixDarunavir/Cobicistat | 70 | $165,497 |
| JulucaDolutegravir/Rilpivirine | 35 | $130,939 |
| TivicayDolutegravir Sodium | 60 | $128,356 |
| DescovyEmtricitabine/Tenofov Alafenam | 18 | $37,994 |
| DovatoDolutegravir Sodium/Lamivudine | 11 | $32,085 |
| OzempicSemaglutide | 17 | $18,271 |
| XareltoRivaroxaban | 25 | $12,948 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 12 | $3,850 |
| Testosterone | 11 | $3,263 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 12 | $1,261 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 28 | $1,053 |
| Tramadol Hcl | 66 | $877 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GileadBiktarvy, Descovy | $21,074 | $987,489265 claims |
| Viiv Healthcare CompanyCabenuva, Juluca, Tivicay, Dovato | $678 | $474,290135 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 105 infectious disease providers in Louisiana.
Other infectious disease in New Orleans
- Eric EhrensingNew Orleans$97K
- Meredith ClementNew Orleans$93K
- Rebecca LillisNew Orleans$60K
- Stephanie TaylorNew Orleans$25K
- Jonathan HandNew Orleans$10K
- Markalain DeryNew Orleans$9K
- Julia Garcia-DiazNew Orleans$8K
- Obinna NneduNew Orleans$3K
- Katherine BaumgartenNew Orleans$3K
- George PankeyNew Orleans$3K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.